Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab.nnLike cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.nnIt has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 κ-chain.nnNimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.
应用类型
Flow cytometry, animal model study
免疫原
Human EGFR / ErbB-1
来源宿主
CHO cells
反应性
Human
保存建议
Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
